Rongtai Health Technology Co., Ltd. in Shanghai Announce on Using Idle Convertible Bond Funds for Cash Management

Security Code: 603579 Security Name: Rongtai Health Announcement No.: 2026-021

Shanghai Rongtai Health Technology Co., Ltd.

Announcement on Using Temporarily Idle Proceeds from Convertible Bonds for Cash Management

The board of directors of this Company and all directors hereby guarantee that the contents of this announcement contain no false records, misleading statements, or material omissions, and assume legal responsibility for the authenticity, accuracy, and completeness of the contents.

Key Points:

● Investment type: broker yield certificates

● Investment amount: RMB 20 million

● Review procedures that have been fulfilled and those proposed to be fulfilled: Shanghai Rongtai Health Technology Co., Ltd. (the “Company,” as hereinafter referred to) held the 21st meeting of the fourth session of the board of directors and the 16th meeting of the fourth session of the board of supervisors on April 23, 2025; held the 2024 annual general meeting of shareholders on May 14, 2025. The Company respectively considered and approved the “Proposal on Using Temporarily Idle Proceeds from Convertible Bonds for Cash Management in 2025,” approving that the Company and its subsidiaries may, in a timely manner, invest the temporarily idle proceeds from publicly issued convertible corporate bonds (hereinafter referred to as “convertible bonds”) in wealth management products or structured deposits with high safety, good liquidity, and low risk, with an aggregate amount not exceeding RMB 450 million. The authorization period shall be within 12 months from the date on which the 2024 annual general meeting of shareholders of the Company approves the proposal. Within the above authorized额度 and authorization period, funds may be jointly used on a rolling basis by the Company and its wholly owned subsidiaries. For details, please refer to the Company’s announcement disclosed on April 24, 2025, titled “Announcement on Using Temporarily Idle Proceeds from Convertible Bonds for Cash Management by Shanghai Rongtai Health Technology Co., Ltd.” (Announcement No.: 2025-023).

● Special Risk Reminder: Although the Company has authorized the use of temporarily idle proceeds to purchase yield certificates with high safety, good liquidity, and low risk, financial markets are greatly influenced by macroeconomic conditions, and the Company does not rule out that entrusted wealth management investments may be affected by market fluctuations. The Company will timely and appropriately intervene based on the economic situation and changes in the financial markets; therefore, the actual investment return in the short term is not predictable.

I. Overview of the Investment

(1) Investment Purpose

Under the premise of ensuring that it does not affect the safety of the proceeds, does not change the use of the proceeds, and does not change the schedule for the use of funds for the proceeds investment projects, the Company uses part of the temporarily idle proceeds from convertible bonds for cash management to maximize the efficiency of the Company’s use of proceeds and to obtain better financial returns for the Company and its shareholders.

(2) Investment Amount

The amount of cash management using temporarily idle proceeds by the Company in this instance is RMB 20 million.

(3) Source of Funds

1. The funds for this wealth management come from the Company’s temporarily idle proceeds from convertible bonds.

2. Approved by the China Securities Regulatory Commission’s “Reply on Approving the Public Issuance of Convertible Corporate Bonds by Shanghai Rongtai Health Technology Co., Ltd.” (CSRC License [2020] No. 2139) and with the approval of the Shanghai Stock Exchange, the Company publicly issued 6 million A-share convertible bonds on October 30, 2020 (each with a par value of RMB 100). The total fund-raising amount was RMB 600,000,000.00. After deducting issuance expenses of RMB 6,017,670.96 (including tax), the actual net proceeds amounted to RMB 593,982,329.04. The above proceeds were fully received on November 5, 2020, and were verified by Cench Hui Accounting Firm (Special General Partnership) through the issuance of “Verification Report on the Funds Raised for Convertible Corporate Bonds in Place” (Cench Hui Verif. [2020] No. 6483).

For details on the use of funds for the Company’s proceeds investment projects, please refer to the Company’s “Special Report on the Storage and Actual Use of Proceeds for the First Half of 2025 by Shanghai Rongtai Health Technology Co., Ltd.” disclosed on August 28, 2025 (Announcement No.: 2025-056).

On November 28, 2025 and December 17, 2025, the Company held the third meeting of the fifth session of the board of directors and the third extraordinary general meeting of shareholders in 2025, respectively, and approved the “Proposal on Changing the Use of Part of Proceeds from Convertible Bonds and Extending the Investment Project Period of Convertible Bond Proceeds.” The Company plans to reduce the investment scale of the original proceeds investment project “Zhejiang Huzhou Nanxun Rongtai Massage Chair Manufacturing Base Project” and extend its timeline, and at the same time change part of the proceeds investment projects to “Construction of Intelligent Massage Equipment and Key Components Manufacturing Project,” “Construction of R&D and Manufacturing for Automotive Seat Comfort Systems Project,” and “Construction of Massage Control System and Data Service Platform Project.” For details, please refer to the Company’s announcement disclosed on December 2, 2025 titled “Announcement on Changing the Use of Part of Proceeds from Convertible Bonds and Extending the Investment Project Period by Shanghai Rongtai Health Technology Co., Ltd.” (Announcement No.: 2025-084).

The following are the proceeds investment projects after the change and extension:

Unit: RMB 10,000

■

Note: As of December 31, 2025, the original proceeds investment project Zhejiang Huzhou Nanxun Rongtai Massage Chair Manufacturing Base Project had an investment progress of 43.14%; the Intelligent Massage Equipment and Key Components Manufacturing Construction Project had an investment progress of 0.67%; the Automotive Seat Comfort Systems R&D and Manufacturing Construction Project had an investment progress of 3.03%; and the Massage Control System and Data Service Platform Construction Project had an investment progress of 0.28%. The above data and project investment progress have not been audited.

(4) Investment Method

1. Basic information of cash management products

■

Note 1: If the end-of-period price < start-of-period price × 100%, the floating yield rate = 0%; if the end-of-period price ≥ start-of-period price × 100%, the floating yield rate = (end-of-period price - start-of-period price × 100%)/start-of-period price × 24%;

Note 2: If the end-of-period price < start-of-period price × 100%, the floating yield rate = 0%; if the end-of-period price ≥ start-of-period price × 100%, the floating yield rate = (end-of-period price - start-of-period price × 100%)/start-of-period price × 27%;

Note 3: If the end-of-period price < start-of-period price × 100%, the floating yield rate = 0%; if the end-of-period price ≥ start-of-period price × 100%, the floating yield rate = (end-of-period price - start-of-period price × 100%)/start-of-period price × 24%;

Note 4: If the end-of-period price < start-of-period price × 100%, the floating yield rate = 0%; if the end-of-period price ≥ start-of-period price × 100%, the floating yield rate = (end-of-period price - start-of-period price × 100%)/start-of-period price × 28%;

2. Key terms of the cash management contract

Product name: Guotai Haitong Securities Junyue Feilong No. 1 Custom 2026 Yield Certificate

Product code: SSGJ93

Product type: Floating yield type.

Settlement currency: RMB

Issuer: Guotai Haitong Securities Co., Ltd.

Subscription date: April 2, 2026

Value date: April 3, 2026

Maturity date: September 28, 2026 (if the maturity date falls on a non-trading day, it will be postponed to the next trading day, and the term will be adjusted accordingly.)

Payment date: the 1st business day after the maturity date (if the payment date is a statutory holiday or a non-business day, it will be postponed to the first business day thereafter)

Initial observation date: April 3, 2026

Final observation date: September 23, 2026

Purchase amount: RMB 5 million

Certificate term: 178 days

Underlying asset: CSI 1000 (000852.SH), bullish direction

Participation rate: 24%

Product risk rating: R1- low

Product name: Guotai Haitong Securities Junyue Feilong No. 50 Custom 2026 Yield Certificate

Product code: SSGJ94

Product type: Floating yield type.

Settlement currency: RMB

Issuer: Guotai Haitong Securities Co., Ltd.

Subscription date: April 2, 2026

Value date: April 3, 2026

Maturity date: September 28, 2026 (if the maturity date falls on a non-trading day, it will be postponed to the next trading day, and the term will be adjusted accordingly.)

Payment date: the 1st business day after the maturity date (if the payment date is a statutory holiday or a non-business day, it will be postponed to the first business day thereafter)

Initial observation date: April 3, 2026

Final observation date: September 23, 2026

Purchase amount: RMB 5 million

Certificate term: 178 days

Underlying asset: SSE 50 (000016.SH), bullish direction

Participation rate: 27%

Product risk rating: R1- low

Product name: Guotai Haitong Securities Junyue Feilong No. 500 Custom 2026 Yield Certificate

Product code: SSGJ91

Product type: Floating yield type.

Settlement currency: RMB

Issuer: Guotai Haitong Securities Co., Ltd.

Subscription date: April 2, 2026

Value date: April 3, 2026

Maturity date: September 28, 2026 (if the maturity date falls on a non-trading day, it will be postponed to the next trading day, and the term will be adjusted accordingly.)

Payment date: the 1st business day after the maturity date (if the payment date is a statutory holiday or a non-business day, it will be postponed to the first business day thereafter)

Initial observation date: April 3, 2026

Final observation date: September 23, 2026

Purchase amount: RMB 5 million

Certificate term: 178 days

Underlying asset: CSI 500 (000905.SH), bullish direction

Participation rate: 24%

Product risk rating: R1- low

Product name: Guotai Haitong Securities Junyue Feilong No. 300 Custom 2026 Yield Certificate

Product code: SSGJ92

Product type: Floating yield type.

Settlement currency: RMB

Issuer: Guotai Haitong Securities Co., Ltd.

Subscription date: April 2, 2026

Value date: April 3, 2026

Maturity date: September 28, 2026 (if the maturity date falls on a non-trading day, it will be postponed to the next trading day, and the term will be adjusted accordingly.)

Payment date: the 1st business day after the maturity date (if the payment date is a statutory holiday or a non-business day, it will be postponed to the first business day thereafter)

Initial observation date: April 3, 2026

Final observation date: September 23, 2026

Purchase amount: RMB 5 million

Certificate term: 178 days

Underlying asset: CSI 300 (000300.SH), bullish direction

Participation rate: 28%

Product risk rating: R1- low

(5) Cash management of proceeds by the Company over the last 12 months up to now

■

Note: If there are rounding differences in the table above, they are due to rounding.

II. Review Procedures

On April 23, 2025, the Company held the 21st meeting of the fourth session of the board of directors and the 16th meeting of the fourth session of the board of supervisors; on May 14, 2025, it held the 2024 annual general meeting of shareholders. The Company respectively considered and approved the “Proposal on Using Temporarily Idle Proceeds from Convertible Bonds for Cash Management in 2025,” agreeing that the Company and its subsidiaries may use, in a timely manner, temporarily idle proceeds from convertible bonds not exceeding RMB 450 million in total amount to invest in wealth management products or structured deposits with high safety, good liquidity, and low risk. The authorization period is within 12 months from the date on which the 2024 annual general meeting of shareholders of the Company approves the proposal. Within the above authorized amount and authorization period, funds may be jointly used on a rolling basis by the Company and its wholly owned subsidiaries. The board of supervisors of the Company issued an approval opinion on the matter, and the sponsor, Vanke Securities Co., Ltd., has no objection to the matter.

For details, please refer to the Company’s announcement disclosed on April 24, 2025 titled “Announcement on Using Temporarily Idle Proceeds from Convertible Bonds for Cash Management by Shanghai Rongtai Health Technology Co., Ltd.” (Announcement No.: 2025-023).

III. Analysis of Investment Risks and Risk Control Measures

1. The underlying assets purchased by the Company and its subsidiaries are wealth management products with high safety and good liquidity, and the risk is controllable.

2. The Company and its subsidiaries have, in accordance with relevant laws and regulations, established and improved special systems for the management of company funds, standardized the approval and execution procedures for cash management, and ensured the effective implementation and standardized operation of cash management matters.

IV. Impact of the Investment on the Company

The Company’s use of temporarily idle proceeds for cash management is implemented on the premise of ensuring that it does not affect the safety of the proceeds, does not change the use of the proceeds, and does not alter the schedule for the use of funds for the proceeds investment projects. This is beneficial for improving the Company’s investment returns and the efficiency of fund usage and does not affect the development of the Company’s main business or the implementation of the proceeds investment projects.

By conducting appropriate cash management, the efficiency of using the proceeds can be improved, and certain investment returns can be obtained, thereby seeking more investment returns for shareholders. The Company does not have any situation in which it purchases large-amount wealth management products while bearing large-amount liabilities. The amount used for cash management using temporarily idle proceeds from convertible bonds in this instance is RMB 20 million, which will not cause material impact on the Company’s future main business, financial position, operating results, and cash flows.

V. Opinions of the Intermediary Institutions

After verification, the sponsor is of the view that:

1. The Company’s proposal to use part of the temporarily idle proceeds from convertible corporate bonds for cash management has been approved by the board of directors and the board of supervisors of the Company, and has completed the necessary approval procedures, which complies with the provisions of the “Guidelines No. 2 on the Supervision of Listed Companies — the Regulatory Requirements for the Management and Use of Proceeds by Listed Companies (Revised in 2022),” the “Self-Regulatory Guidelines No. 1 for Listed Companies on the Shanghai Stock Exchange — Standardized Operation (Revised in December 2023),” and other relevant laws and regulations;

2. The matter of conducting cash management with temporarily idle proceeds does not violate the relevant commitments regarding proceeds investment projects, does not affect the normal progress of the proceeds investment projects, and there is no situation of indirectly changing the proceeds investment projects or harming the interests of shareholders;

3. Subject to ensuring the normal construction of the Company’s proceeds projects, not changing the use of the proceeds, and ensuring the Company’s normal business funding needs and fund safety, as well as that investment risks are effectively controlled, through cash management the Company can improve the efficiency of using funds, obtain certain returns, and this complies with the interests of the Company and all shareholders. The sponsor has no objection to the Company’s matter of using part of the temporarily idle proceeds for cash management.

Hereby, this announcement is issued.

Board of Directors of Shanghai Rongtai Health Technology Co., Ltd.

April 3, 2026

Security Code: 603579 Security Name: Rongtai Health Announcement No.: 2026-020

Shanghai Rongtai Health Technology Co., Ltd.

Announcement on the Shareholding of the Top Ten Shareholders

and the Top Ten Shareholders with No Restrictions on Selling Shares Prior to the Share Repurchase

The board of directors of this Company and all directors hereby guarantee that the contents of this announcement contain no false records, misleading statements, or material omissions, and assume legal responsibility for the authenticity, accuracy, and completeness of the contents.

On March 30, 2026, the board of directors of Shanghai Rongtai Health Technology Co., Ltd. (the “Company,” as hereinafter referred to) reviewed and approved at the 7th meeting of the fifth session of the board of directors the “Proposal on Upholding the Company’s Value and Shareholders’ Rights and Interests and Repurchasing the Company’s Shares by Means of Centralized Bidding.” The Company agreed to repurchase its shares by using its own funds through centralized bidding transactions and to use all repurchased shares for maintaining the Company’s value and the shareholders’ rights and interests, with subsequent sale using centralized bidding transactions. The total repurchase fund amount shall not be less than RMB 50 million (inclusive) and not exceed RMB 100 million (inclusive), the repurchase price shall not exceed RMB 33.00 per share (inclusive), and the repurchase period shall be within 3 months from the date on which the board of directors approves the share repurchase plan. For details, please refer to the Company’s “Repurchase Report” disclosed on March 31, 2026 titled “Announcement on Upholding the Company’s Value and Shareholders’ Rights and Interests and Repurchasing Shares by Means of Centralized Bidding” (Announcement No.: 2026-017).

In accordance with relevant provisions such as the “Rules for Share Repurchase of Listed Companies,” and the “Self-Regulatory Guidelines No. 7 — Share Repurchases” of the Shanghai Stock Exchange, the Company hereby announces the names, shareholding quantities, and shareholding proportions of the top ten shareholders and the top ten shareholders with no restrictions on selling shares recorded as of the previous trading day of the board of directors’ announcement (i.e., March 30, 2026), as follows:

■

Hereby, this announcement is issued.

Board of Directors of Shanghai Rongtai Health Technology Co., Ltd.

April 3, 2026

A large amount of information and precise interpretation are available on Sina Finance APP